Navigation Links
Combination Products Executive Forum to be Hosted by CHI's Pharmaceutical Strategy Series
Date:2/13/2009

Business Executives, Pricing Analysts, and IP Professionals Meet on Expanding their Combination Products Research and Partnerships on June 1-2, 2009 in Cambridge, MA.

Needham, MA (PRWEB) February 13, 2009 -- The Pharmaceutical Strategy Series, a division of Cambridge Healthtech Institute, recently posted details for its next executive forum - Combination Products: Improving Product Life Cycles, Extending Lines, and Creating Novel Therapeutics to be held on June 1-2, 2009 at the Royal Sonesta Hotel in Cambridge, MA. This executive forum will focus on the practical interplay between combination product research, development challenges, and commercial and partnering strategies, as well as the implications for successful market realization.

Session Topics include:

  • Creative Product Development, Portfolio Management, and Line Extension Strategies using Combination Products
  • Regulatory Implications - Anticipating Regulatory Hurdles and New Developments
  • The Market Advantage of Combination Products - Analysis and Strategies for Positioning
  • Commercial Strategies for Success - Market Acceptance and Reimbursement
  • Development Challenges of Combination Products

According to Micah Lieberman, Executive Director of the Pharmaceutical Strategy Series, "We are delighted to have organized this executive forum for the pharmaceutical, biologics and medical devices industries to help companies leverage new business opportunities and intellectual property for their existing (and future) products. Pharmaceutical Strategy Series' executive forums have become known as networking platforms that bring together senior-level executives, analysts, and industry experts. I am also pleased to announce the support of Epstein Becker & Green, P.C. as our sponsor," states Lieberman.

Bradley Merrill Thompson, General Counsel to the Combination Products Coalition and Shareholder at Epstein Becker & Green, P.C. commented: "We look forward to present our perspective on overcoming the regulatory hurdles with combination products. To be compliant and competitive in the marketplace, combination product companies must stay current with regulatory developments and initiatives impacting the combination product industry. Delegates attending this conference will be better positioned to ensure the success of their company's combination products," says Thompson.

Prior to the start of this executive forum will be a pre-conference workshop: Economic Value-Based Product Design for Combination Drugs.

For full details and to register for the conference and/or pre-conference workshop, visit www.healthtech.com/CTX/overview.aspx

To receive a press pass, email Tracey Fielding at tfielding@healthtech.com

About Cambridge Healthtech Institute
Founded in 1992, Cambridge Healthtech Institute (www.chicorporate.com) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations. CHI's portfolio of products includes Cambridge Healthtech Institute Conferences, Insight Pharma Reports, Cambridge Marketing Consultants, Cambridge Meeting Planners and Cambridge Healthtech's Media Group, which includes numerous e-newsletters as well as Bio-IT World magazine.

Founded in 1992, Cambridge Healthtech Institute strives to develop quality information sources that provide valuable new insights and competing points of view while offering balanced coverage of the latest developments. Basic research related to commercial implications is covered, with heavy emphasis placed on end-user insights into new products and technology as well as coverage on the strategy behind the business.

About The Pharmaceutical Strategy Series
A division of Cambridge Healthtech Institute, the Pharmaceutical Strategy Series (www.PharmaSeries.com) produces executive-level conferences that bring together R&D leaders and corporate executives to assess business opportunities, enhance corporate value, and forecast the economic and regulatory landscape within the rapidly changing pharmaceutical & biotechnology industries. PSS conferences are uniquely designed to maximize peer-to-peer networking and idea sharing.

Contact:
James Prudhomme
Cambridge Healthtech Institute
(781) 972-5400

# # #

Read the full story at http://www.prweb.com/releases/2009/02/prweb2051004.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. PREZISTA(R) Now Available for Pediatric Patients Six Years of Age and Older as part of HIV Combination Therapy
2. Biomarker Combination and Risk of Ovarian Malignancy Algorithm (Roma(TM)) Demonstrates Accuracy in Detecting Ovarian Cancer
3. If Herceptin is Approved in Combination With Other Emerging Therapies it Will be in a Position to Retain Patient Share From Tykerb/Tyverb for the Treatment of HER2-Positive Breast Cancer
4. Drug combinations key in treating neurodegenerative diseases
5. InterMune Reports Results from Triple Combination Study of ITMN-191
6. Scientists call up stem cell troops to repair the body using new drug combinations
7. DrScore.com Identifies Toxic Combination
8. Galderma Announces Availability of Epiduo(TM) Gel, the First and Only Combination Treatment with a Retinoid and Benzoyl Peroxide to Treat Acne
9. Drug Combinations Putting Seniors at Risk
10. Holiday Treats and Decorations Can Be a Deadly Combination for Pets
11. QLT announces interim results of radical study evaluating Visudyne combination therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2017)... ... June 27, 2017 , ... ... according to survey data released today by the American Society for Dermatologic ... indicates the percentage of consumers considering a cosmetic medical procedure has doubled ...
(Date:6/27/2017)... (PRWEB) , ... June 27, 2017 , ... Harbour ... manage token assets on the Ethereum blockchain, has released their technical specifications . ... now, there has been little systematic approach for determining which offerings will garner the ...
(Date:6/27/2017)... ... June 27, 2017 , ... The Congressional Budget Office (CBO) projects ... replace the 2010 Patient Protection and Affordable Care Act (ACA), would result in 22 ... expected under current law. , More than 20 million Americans have gained health insurance ...
(Date:6/27/2017)... ... ... From June 20-22, EarQ and Widex held an exclusive training ... EarQ is headquartered. , Together, the organizations educate hearing care professionals on how ... the latest in hearing technology. At the event, EarQ members got an in-depth ...
(Date:6/27/2017)... ... ... Two residents from the Gardant-managed assisted living and memory care communities in South ... protect Medicaid funding. , The video, which was produced by the American Health Care ... Cathy Schwarz, a couple who is still able to see each other every day ...
Breaking Medicine News(10 mins):
(Date:6/7/2017)... , June 7, 2017  Novavax, Inc., (Nasdaq: ... of two Phase 2 trials of its RSV F protein ... child bearing age have been published in the journal ... have been shared in prior scientific conferences). The Company previously ... April 2014. Novavax is developing the RSV F Vaccine with ...
(Date:6/2/2017)... -- NxStage Medical, Inc. (Nasdaq:  NXTM), a leading medical technology company focused ... positive biochemical outcomes related to more frequent hemodialysis with ... be presented at the ERA-EDTA Congress being held June ... The research was conducted by the ... Europe (KIHDNEy) Cohort team with ...
(Date:5/29/2017)... Biotechnology Ltd. (NASDAQ: APOP ; TASE: APOP), a ... of stem cells, today provided a corporate update and ... 31 st , 2017. "We are ... of 2017," said Dr. Shai Yarkoni, Chief Executive Officer. ... the first blood cancer patient in the recently initiated ...
Breaking Medicine Technology: